JP5234445B2 - 薬剤 - Google Patents

薬剤 Download PDF

Info

Publication number
JP5234445B2
JP5234445B2 JP2005292596A JP2005292596A JP5234445B2 JP 5234445 B2 JP5234445 B2 JP 5234445B2 JP 2005292596 A JP2005292596 A JP 2005292596A JP 2005292596 A JP2005292596 A JP 2005292596A JP 5234445 B2 JP5234445 B2 JP 5234445B2
Authority
JP
Japan
Prior art keywords
killed
suspension
bacterial
medium
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005292596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006131623A5 (enExample
JP2006131623A (ja
Inventor
邦雄 瀧口
裕之 稲川
千恵 河内
孝志 西澤
源一郎 杣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2005292596A priority Critical patent/JP5234445B2/ja
Publication of JP2006131623A publication Critical patent/JP2006131623A/ja
Publication of JP2006131623A5 publication Critical patent/JP2006131623A5/ja
Application granted granted Critical
Publication of JP5234445B2 publication Critical patent/JP5234445B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2005292596A 2004-10-05 2005-10-05 薬剤 Expired - Lifetime JP5234445B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005292596A JP5234445B2 (ja) 2004-10-05 2005-10-05 薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004293121 2004-10-05
JP2004293121 2004-10-05
JP2005292596A JP5234445B2 (ja) 2004-10-05 2005-10-05 薬剤

Publications (3)

Publication Number Publication Date
JP2006131623A JP2006131623A (ja) 2006-05-25
JP2006131623A5 JP2006131623A5 (enExample) 2006-09-14
JP5234445B2 true JP5234445B2 (ja) 2013-07-10

Family

ID=36725477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005292596A Expired - Lifetime JP5234445B2 (ja) 2004-10-05 2005-10-05 薬剤

Country Status (1)

Country Link
JP (1) JP5234445B2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP5361132B2 (ja) * 2006-03-10 2013-12-04 国立大学法人信州大学 免疫グロブリンｇを含有する経口用免疫調節剤、その製造方法及び経口用免疫調節剤を配合してなる飲食品
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2008179572A (ja) * 2007-01-25 2008-08-07 Shinshu Univ 免疫グロブリンＦｃフラグメントレセプタータンパク及び／又は免疫グロブリンＦｃフラグメントレセプター様タンパク産生抑制剤及びその使用
ES2645509T3 (es) 2010-07-26 2017-12-05 Qu Biologics Inc Composiciones antiinflamatorias inmunogénicas
HUE064945T2 (hu) 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
SI2892927T1 (sl) * 2012-09-07 2018-10-30 Regeneron Pharmaceuticals,Inc Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
KR20160024916A (ko) 2013-06-21 2016-03-07 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
CA3254723A1 (en) 2014-05-02 2025-04-15 Qu Biologics Inc ANTIMICROBIAL IMMUNOMODULATION
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
MX2021011141A (es) 2019-03-21 2022-01-19 Regeneron Pharma Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4010001A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920220A (ja) * 1982-07-23 1984-02-01 Yakult Honsha Co Ltd 損傷皮膚創面治療剤
JP4024454B2 (ja) * 2000-03-31 2007-12-19 日本甜菜製糖株式会社 ＩｇＥ抗体産生低減剤およびアレルギー体質改善剤
ES2260078T3 (es) * 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
EP1228767A1 (en) * 2001-01-31 2002-08-07 S.A.R.M. S.r.l. Use of beta-Glucuronidase for the treatment of immune or allergic diseases
JP2003063972A (ja) * 2001-08-23 2003-03-05 Morinaga & Co Ltd 抗アレルギー剤
JP4618970B2 (ja) * 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤

Also Published As

Publication number Publication date
JP2006131623A (ja) 2006-05-25

Similar Documents

Publication Publication Date Title
JP5234445B2 (ja) 薬剤
Shapouri‐Moghaddam et al. Macrophage plasticity, polarization, and function in health and disease
Mei et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis
Goldbach-Mansky Current status of understanding the pathogenesis and management of patients with NOMID/CINCA
Martinet et al. Differential expression of the tumor necrosis factor/cachectin gene by blood and lung mononuclear phagocytes
Yli-Karjanmaa et al. Topical administration of a soluble TNF inhibitor reduces infarct volume after focal cerebral ischemia in mice
Chen et al. Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells
Miao et al. Injecting immunosuppressive M2 macrophages alleviates the symptoms of periodontitis in mice
Zhang et al. Therapeutic strategies by regulating interleukin family to suppress inflammation in hypertrophic scar and keloid
Monteiro et al. Pivotal role of the 5-lipoxygenase pathway in lung injury after experimental sepsis
Liu et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection
Mihaylova et al. Effects of anti-inflammatory vagus nerve stimulation in endotoxemic rats on blood and spleen lymphocyte subsets
JP2015500820A (ja) Ｅｇｆｒ阻害の有害反応を予防または処置するための組成物
JP5671506B2 (ja) 細胞膜媒介性作用の調節
Koth et al. Aspergillus antigen induces robust Th2 cytokine production, inflammation, airway hyperreactivity and fibrosis in the absence of MCP-1 or CCR2
Park et al. Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis
JP2025026493A (ja) 自然リンパ系細胞による小膠細胞活性化の抑制
WO2025140008A1 (zh) 重组蛋白ccl11在治疗恶性胸腔积液中的应用
WO2023227087A1 (en) Plectranthus amboinicus extract for use in inhibiting immune responses
US20170014484A1 (en) Methods of Promotion of Healing of Diabetic Wounds
Laulund et al. Adjunctive S100A8/A9 immunomodulation hinders ciprofloxacin resistance in Pseudomonas aeruginosa in a murine biofilm wound model
JP2009519254A (ja) 創傷治癒過程を改善するウシオステオポンチン製剤
CN106063929B (zh) 用于促进伤口愈合的吴郭鱼抗菌胜肽
Furudoi et al. Balance of tumor necrosis factor alpha and interleukin-10 in a buccal infection in a streptozotocin-induced diabetic rat model
Bazikov et al. Results of exposure of endogenous antimicrobial peptides to ESKAPE-pathogens in experiment

Legal Events

Date Code Title Description
A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20060614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130315

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5234445

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160405

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250